Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer
Author:
Funder
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Publisher
Springer Science and Business Media LLC
Link
https://link.springer.com/content/pdf/10.1007/s00109-024-02431-x.pdf
Reference179 articles.
1. Ferlay J, Colombet M, Soerjomataram I et al (2021) Cancer statistics for the year 2020: an overview. Int J cancer. https://doi.org/10.1002/ijc.33588
2. Desai A, Scheckel C, Jensen CJ et al (2022) Trends in prices of drugs used to treat metastatic non-small cell lung cancer in the US from 2015 to 2020. JAMA Netw open 5:e2144923. https://doi.org/10.1001/jamanetworkopen.2021.44923
3. Peng L, Wang Z, Stebbing J, Yu Z (2022) Novel immunotherapeutic drugs for the treatment of lung cancer. Curr Opin Oncol 34:89–94. https://doi.org/10.1097/CCO.0000000000000800
4. Xu M, Peng R, Min Q et al (2022) Bisindole natural products: a vital source for the development of new anticancer drugs. Eur J Med Chem 243:114748. https://doi.org/10.1016/j.ejmech.2022.114748
5. Zigrossi A, Hong LK, Ekyalongo RC et al (2022) SELENOF is a new tumor suppressor in breast cancer. Oncogene 41:1263–1268. https://doi.org/10.1038/s41388-021-02158-w
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Erythropoietin-induced hepatocyte receptor A2 regulates effect of pyroptosis on gastrointestinal colorectal cancer occurrence and metastasis resistance;World Journal of Gastrointestinal Oncology;2024-09-15
2. Ephrin receptor type-A2 (EphA2) targeting in cancer: a patent review (2018–present);Expert Opinion on Therapeutic Patents;2024-09-11
3. Sesamol-mediated targeting of EPHA2 sensitises cervical cancer for cisplatin treatment by regulating mitochondrial dynamics, autophagy, and mitophagy;Molecular Biology Reports;2024-09-02
4. Therapeutic advances of targeting receptor tyrosine kinases in cancer;Signal Transduction and Targeted Therapy;2024-08-14
5. Biological mechanisms of resistance to trastuzumab and ways to overcome them: Mod-ern problems of clinical oncology;Regulatory Mechanisms in Biosystems;2024-05-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3